公司概述
Lantheus Holdings, Inc. specializes in the development, manufacturing, and commercialization of diagnostic and therapeutic products designed to assist clinicians in diagnosing and treating conditions such as heart disease, cancer, and other diseases globally. Within the Healthcare sector, the company operates specifically within the Drug Manufacturers - Specialty & Generic industry, a segment focused on producing specialized pharmaceuticals and medical agents for niche therapeutic areas. The company maintains a substantial market capitalization of $5.30B, generates annual revenue of $1.54B, and employs a workforce of 1193 individuals. These financial figures indicate that Lantheus Holdings occupies a significant position within its niche, supported by a robust revenue stream that underpins its market valuation and operational scale.
财务健康
The company reported a Trailing Twelve Months (TTM) revenue of $1.54B with a corresponding net income of $233.56M and an EBITDA of $382.31M. The substantial gap between the $1.54B revenue and the $233.56M net income reveals a cost structure where operating expenses, including Cost of Goods Sold, general, and administrative costs, consume approximately 84.8% of total revenue before reaching the bottom line. Free cash flow stands at $265.57M, which signifies strong financial flexibility allowing the firm to fund operations, service debt, or pursue strategic initiatives without relying heavily on external financing. The company demonstrates healthy profitability across multiple margins: a Gross Margin of 61.1% indicates efficient production and pricing power, an Operating Margin of 19.1% reflects effective cost management relative to sales, and a Profit Margin of 15.2% shows the final percentage of revenue retained as net earnings. Regarding liquidity and leverage, the firm holds $359.12M in cash against $623.24M in total debt, resulting in a Debt to Equity ratio of 57.19, which suggests a levered balance sheet where debt levels are nearly equal to equity capitalization. The Current Ratio of 2.70 indicates that current assets are more than twice current liabilities, pointing to a conservative approach to short-term liquidity management. Return on Equity of 21.4% and Return on Assets of 9.3% reveal that management is effectively utilizing shareholder equity and total assets to generate returns, with equity generating returns at more than double the asset base efficiency.
估值评估
The valuation metrics present a trailing P/E ratio of 23.88 and a forward P/E of 12.94. The significant difference between these two ratios implies that the market expects earnings growth that will substantially reduce the forward multiple relative to the current historical earnings base. The Price to Book ratio is 4.83, which indicates that the stock trades at a substantial premium over its book value, reflecting investor confidence in the company's intangible assets and future growth potential rather than just its net tangible assets. Alternative valuation metrics include a Price to Sales ratio of 3.44 and an EV/EBITDA of 14.45, suggesting the market values the company based on a multiple of its sales and earnings before interest, taxes, depreciation, and amortization that is moderate for a specialty pharmaceutical firm. The stock has traded between a 52-week low of $47.25 and a 52-week high of $108.91, and without the specific current share price provided in the facts, the precise percentage deviation from these bounds cannot be calculated, though the range highlights the volatility experienced over the past year. The Beta is recorded at -0.12, which is an anomalous value for a large-cap stock and suggests an inverse correlation to the broader market or a data anomaly, indicating price movements that theoretically move in the opposite direction of the market index rather than with it.
Growth & Income
Revenue growth year-over-year is recorded at 4.0%, while earnings growth year-over-year is listed as N/A. The absence of a quantified earnings growth rate precludes a direct comparison of earnings versus revenue expansion, though the positive revenue growth suggests underlying demand for its diagnostic and therapeutic products is expanding. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the firm reinvests all its earnings into business growth, R&D, or capital expenditures rather than distributing cash to shareholders. This strategy aligns with the company's focus on developing and commercializing new products in the heart, cancer, and other disease treatment markets to drive long-term value creation. Overall, the growth and income profile is characterized by moderate revenue expansion in a specialized healthcare sector with a current focus on internal reinvestment rather than income generation through dividends.